Effect of secukinumab versus adalimumab biosimilar on radiographic progression in patients with radiographic axial spondyloarthritis: Results from a head-to-head randomized phase IIIb study.
Xenofon BaraliakosMikkel ØstergaardDenis PoddubnyyDésirée van der HeijdeAtul A DeodharPedro M MachadoVictoria Navarro-CompánKay-Geert A HermannKishimoto MitsumasaEun Young LeeLianne S GenslerUta KiltzMarco F EigenmannPatricia PertelAimee ReadieHanno B RichardsBrian PorterJuergen BraunPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2024)
Spinal radiographic progression over 2 years was low with no significant difference between secukinumab and SDZ-ADL arms. The safety of both treatments was consistent with previous reports.